INVESTORS

AT A GLANCE

Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Our solutions use clinical algorithms to deliver personalized recommendations to patients and their care teams. Leveraging our Theraxium technology platform, we have designed and operates multiple digital therapeutics, especially in oncology and diabetes. With an experience of nearly 20 years in the industry, we have long-standing partnerships with leading life science companies and are a founding member of the Digital Therapeutics Alliances. 

STOCK INFORMATION

EURONEXT Paris

WHAT'S NEW

Upcoming events

30 Mar. 2021

2020 Annual Results

2020 H1 Results

NEWS

Voluntis receives CE Mark for Oleena

PRESS RELEASES

DOCUMENTS

No documents match your search. Please choose different criteria.

CONTACT THE INVESTOR RELATIONS TEAM

Actus
Jérôme Fabreguettes-Leib

Tel: +33 (0)1 53 67 36 78
Email: voluntis@actus.fr